BACKGROUND: Double-cord-blood transplantation (DCBT) offers an option for patients receiving reduced-intensity transplants. These unique transplants have two donors, both of whom are usually HLA mismatched at one to two loci. STUDY DESIGN AND METHODS: Fifty-three patients were recipients of a reduced-intensity DCBT. Cords were at least 4/6 allele-level HLA-A, -B, and -DR match with the patient and each other with a minimum combined cell dose of more than 3.7 x 10(7) total nucleated cells per kg. Twenty-one patients received cyclosporine/mycophenolate mofetil and 32 patients received sirolimus/tacrolimus (SIR/TAC) for graft-versus-host disease prophylaxis. The effect of allele level HLA typing on clinical endpoints of overall survival (OS), disease-free survival (DFS), engraftment, and acute graft-versus-host disease (aGVHD) were assessed. RESULTS: Neutrophil (p = 0.001) engraftment and platelet engraftment (p = 0.027) were significantly faster in patients who have closer Class I (HLA-A, -B, -C) matching. Neutrophil engraftment was faster in patients who had closer HLA-B matching to their combined cords (p = 0.007). There was a low incidence of aGVHD overall, especially in the SIR/TAC group. Class I HLA matching had no effect on aGVHD. HLA-DR and -DQ had no effect on engraftment or aGVHD. CONCLUSION: Class I allele matching, and HLA-B matching specifically, were associated with faster neutrophil engraftment. High-resolution HLA matching did not affect OS or DFS.
BACKGROUND: Double-cord-blood transplantation (DCBT) offers an option for patients receiving reduced-intensity transplants. These unique transplants have two donors, both of whom are usually HLA mismatched at one to two loci. STUDY DESIGN AND METHODS: Fifty-three patients were recipients of a reduced-intensity DCBT. Cords were at least 4/6 allele-level HLA-A, -B, and -DR match with the patient and each other with a minimum combined cell dose of more than 3.7 x 10(7) total nucleated cells per kg. Twenty-one patients received cyclosporine/mycophenolate mofetil and 32 patients received sirolimus/tacrolimus (SIR/TAC) for graft-versus-host disease prophylaxis. The effect of allele level HLA typing on clinical endpoints of overall survival (OS), disease-free survival (DFS), engraftment, and acute graft-versus-host disease (aGVHD) were assessed. RESULTS: Neutrophil (p = 0.001) engraftment and platelet engraftment (p = 0.027) were significantly faster in patients who have closer Class I (HLA-A, -B, -C) matching. Neutrophil engraftment was faster in patients who had closer HLA-B matching to their combined cords (p = 0.007). There was a low incidence of aGVHD overall, especially in the SIR/TAC group. Class I HLA matching had no effect on aGVHD. HLA-DR and -DQ had no effect on engraftment or aGVHD. CONCLUSION: Class I allele matching, and HLA-B matching specifically, were associated with faster neutrophil engraftment. High-resolution HLA matching did not affect OS or DFS.
Authors: E Gluckman; H A Broxmeyer; A D Auerbach; H S Friedman; G W Douglas; A Devergie; H Esperou; D Thierry; G Socie; P Lehn Journal: N Engl J Med Date: 1989-10-26 Impact factor: 91.245
Authors: E W Petersdorf; C Kollman; C K Hurley; B Dupont; A Nademanee; A B Begovich; D Weisdorf; P McGlave Journal: Blood Date: 2001-11-15 Impact factor: 22.113
Authors: H E Broxmeyer; G W Douglas; G Hangoc; S Cooper; J Bard; D English; M Arny; L Thomas; E A Boyse Journal: Proc Natl Acad Sci U S A Date: 1989-05 Impact factor: 11.205
Authors: P Rubinstein; L Dobrila; R E Rosenfield; J W Adamson; G Migliaccio; A R Migliaccio; P E Taylor; C E Stevens Journal: Proc Natl Acad Sci U S A Date: 1995-10-24 Impact factor: 11.205
Authors: Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Bruce R Blazar; Jeffrey S Miller; John E Wagner Journal: Blood Date: 2003-05-08 Impact factor: 22.113
Authors: John E Wagner; Juliet N Barker; Todd E DeFor; K Scott Baker; Bruce R Blazar; Cindy Eide; Anne Goldman; John Kersey; William Krivit; Margaret L MacMillan; Paul J Orchard; Charles Peters; Daniel J Weisdorf; Norma K C Ramsay; Stella M Davies Journal: Blood Date: 2002-09-01 Impact factor: 22.113
Authors: Effie W Petersdorf; Claudio Anasetti; Paul J Martin; Ted Gooley; Jerald Radich; Mari Malkki; Ann Woolfrey; Anajane Smith; Eric Mickelson; John A Hansen Journal: Blood Date: 2004-07-13 Impact factor: 22.113
Authors: J Styczynski; Y-K Cheung; J Garvin; D G Savage; G B Billote; L Harrison; D Skerrett; K Wolownik; C Wischhover; R Hawks; M B Bradley; G Del Toro; D George; D Yamashiro; C van de Ven; M S Cairo Journal: Bone Marrow Transplant Date: 2004-07 Impact factor: 5.483
Authors: Neal Flomenberg; Lee Ann Baxter-Lowe; Dennis Confer; Marcelo Fernandez-Vina; Alexandra Filipovich; Mary Horowitz; Carolyn Hurley; Craig Kollman; Claudio Anasetti; Harriet Noreen; Ann Begovich; William Hildebrand; Effie Petersdorf; Barbara Schmeckpeper; Michelle Setterholm; Elizabeth Trachtenberg; Thomas Williams; Edmond Yunis; Daniel Weisdorf Journal: Blood Date: 2004-06-10 Impact factor: 22.113
Authors: D M Ponce; A Gonzales; M Lubin; H Castro-Malaspina; S Giralt; J D Goldberg; A M Hanash; A Jakubowski; R Jenq; E B Papadopoulos; M A Perales; M R M van den Brink; J W Young; F Boulad; R J O'Reilly; S Prockop; T N Small; A Scaradavou; N A Kernan; C E Stevens; J N Barker Journal: Biol Blood Marrow Transplant Date: 2013-02-14 Impact factor: 5.742
Authors: Corey Cutler; Haesook T Kim; Lixian Sun; Doreen Sese; Brett Glotzbecker; Philippe Armand; John Koreth; Vincent Ho; Edwin Alyea; Karen Ballen; Jerome Ritz; Robert J Soiffer; Edgar Milford; Joseph H Antin Journal: Blood Date: 2011-09-22 Impact factor: 22.113
Authors: J Pidala; J Kim; M Schell; S J Lee; R Hillgruber; V Nye; E Ayala; M Alsina; B Betts; R Bookout; H F Fernandez; T Field; F L Locke; T Nishihori; J L Ochoa; L Perez; J Perkins; J Shapiro; C Tate; M Tomblyn; C Anasetti Journal: Bone Marrow Transplant Date: 2012-08-06 Impact factor: 5.483
Authors: M Gotoh; S Yoshizawa; S Katagiri; T Suguro; M Asano; T Kitahara; D Akahane; S Okabe; T Tauchi; Y Ito; K Ohyashiki Journal: Bone Marrow Transplant Date: 2014-04-14 Impact factor: 5.483
Authors: Corey Cutler; Pratik Multani; David Robbins; Haesook T Kim; Thuy Le; Jonathan Hoggatt; Louis M Pelus; Caroline Desponts; Yi-Bin Chen; Betsy Rezner; Philippe Armand; John Koreth; Brett Glotzbecker; Vincent T Ho; Edwin Alyea; Marlisa Isom; Grace Kao; Myriam Armant; Leslie Silberstein; Peirong Hu; Robert J Soiffer; David T Scadden; Jerome Ritz; Wolfram Goessling; Trista E North; John Mendlein; Karen Ballen; Leonard I Zon; Joseph H Antin; Daniel D Shoemaker Journal: Blood Date: 2013-08-30 Impact factor: 22.113
Authors: T L Kindwall-Keller; Y Hegerfeldt; H J Meyerson; S Margevicius; P Fu; W van Heeckeren; H M Lazarus; B W Cooper; S L Gerson; P Barr; W W Tse; C Curtis; L R Fanning; R J Creger; J M Carlson-Barko; M J Laughlin Journal: Bone Marrow Transplant Date: 2011-10-17 Impact factor: 5.483